For example, in a phase 2 pilot study of 46 CML patients, patients who did not achieve major molecular response (MMR) at 18 months of treatment with imatinib or dasatinib had Ph+ cells (> 75%) in the CD34+CD38- fraction (154). Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.